← Issue №10/ week of Sep 6, 2026/Motility

Ameliorating Effects and Autonomic Mechanisms of Transcutaneous Auricular Vagus Nerve Stimulation on Abdominal Pain in Patients With Functional Dyspepsia and Irritable Bowel Syndrome.

From GI Signals issue №10: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Motility rct · n=64 · Sep 1, 2026 · Neurogastro Motil · IF 3.5

Ameliorating Effects and Autonomic Mechanisms of Transcutaneous Auricular Vagus Nerve Stimulation on Abdominal Pain in Patients With Functional Dyspepsia and Irritable Bowel Syndrome.

New evidenceIBSfunctional dyspepsiabasic sciencetranslational
Clinical takeawayConsider taVNS as a non-invasive adjunct therapy for refractory abdominal pain in FD and IBS patients after standard treatments (PPI, neuromodulators) fail.
What it foundtaVNS reduced abdominal pain scores (p < 0.001) and frequency (p < 0.001) vs sham-taVNS in FD and IBS patients, with no difference in effect between the two conditions.
ContextThis exploratory RCT provides preliminary evidence supporting taVNS for symptom relief in functional GI disorders, aligning with growing interest in neuromodulation therapies. Safety data were not reported in the abstract.
Emergingsuggested applicable standard· American College of Gastroenterology, 'ACG and CAG Clinical Guideline: Management of Dyspepsia', 2017

Decision at stakeconsidering non-pharmacological interventions for refractory functional dyspepsia

After excluding organic causes and confirming H. pylori test-of-cure, manage functional dyspepsia by eradicating H. pylori if positive and giving a PPI (4-8 weeks, dosed 30-60 min before meals); for persistent symptoms consider neuromodulators (e.g., low-dose TCAs like amitriptyline 10-50 mg QHS) for refractory cases, particularly in EPS, or prokinetics cautiously in selected PDS cases. Initial evaluation follows ACG/CAG 2017: test-and-treat H. pylori in patients under 60 without alarm features, and EGD for age ≥60, alarm features, or high gastric-cancer-risk groups. Add psychological therapies (CBT, gut-directed hypnotherapy) and lifestyle measures.

American College of Gastroenterology, 'ACG and CAG Clinical Guideline: Management of Dyspepsia', 2017 · reviewed 2026-07-21 ↗
Sun X … Chen JDZ · Neurogastroenterology and Motility · IF 3.5 · PubMed ↗Permalink
← Read the whole of issue №10 Every paper GI Signals surfaces gets a page like this one. All issues